BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ratziu V. Non-pharmacological interventions in non-alcoholic fatty liver disease patients. Liver Int 2017;37 Suppl 1:90-6. [PMID: 28052636 DOI: 10.1111/liv.13311] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Theel W, Boxma-de Klerk BM, Dirksmeier-Harinck F, van Rossum EFC, Kanhai DA, Apers J, van Dalen BM, de Knegt RJ, Holleboom AG, Tushuizen ME, Grobbee DE, Wiebolt J, Castro Cabezas M. Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques. Obes Rev 2022. [PMID: 35692179 DOI: 10.1111/obr.13481] [Reference Citation Analysis]
2 Charatcharoenwitthaya P, Tansakul E, Chaiyasoot K, Bandidniyamanon W, Charatcharoenwitthaya N. Dietary Composition and Its Association with Newly Diagnosed Nonalcoholic Fatty Liver Disease and Insulin Resistance. Nutrients 2021;13:4438. [PMID: 34959990 DOI: 10.3390/nu13124438] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Roberts SK, Majeed A. A short report on NGM282/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Ther Targets 2021;25:889-95. [PMID: 34727818 DOI: 10.1080/14728222.2021.1999416] [Reference Citation Analysis]
4 Lazarus JV, Anstee QM, Hagström H, Cusi K, Cortez-Pinto H, Mark HE, Roden M, Tsochatzis EA, Wong VW, Younossi ZM, Zelber-Sagi S, Romero-Gómez M, Schattenberg JM. Defining comprehensive models of care for NAFLD. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34172937 DOI: 10.1038/s41575-021-00477-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 25.0] [Reference Citation Analysis]
5 Rajabi S, Askari R, Haghighi AH, Razavianzadeh N. The Effects of Two Different Intensities of Combined Training on C1q/TNF-Related Protein 3 (CTRP3) and Insulin Resistance in Women with Non-alcoholic Fatty Liver Disease. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.108106] [Reference Citation Analysis]
6 Garousi N, Tamizifar B, Pourmasoumi M, Feizi A, Askari G, Clark CCT, Entezari MH. Effects of lacto-ovo-vegetarian diet vs. standard-weight-loss diet on obese and overweight adults with non-alcoholic fatty liver disease: a randomised clinical trial. Arch Physiol Biochem 2021;:1-9. [PMID: 33689525 DOI: 10.1080/13813455.2021.1890128] [Reference Citation Analysis]
7 Kenđel Jovanović G, Mrakovcic-Sutic I, Pavičić Žeželj S, Benjak Horvat I, Šuša L, Rahelić D, Klobučar Majanović S. Metabolic and Hepatic Effects of Energy-Reduced Anti-Inflammatory Diet in Younger Adults with Obesity. Can J Gastroenterol Hepatol 2021;2021:6649142. [PMID: 33628758 DOI: 10.1155/2021/6649142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
8 Schröder B, Roden M. Was bedeuten die neuen Diabetessubgruppen für Menschen mit Fettlebererkrankung? Diabetologe 2021;17:20-5. [DOI: 10.1007/s11428-020-00698-5] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Carneros D, López-Lluch G, Bustos M. Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients 2020;12:E3472. [PMID: 33198247 DOI: 10.3390/nu12113472] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
10 Ai L, Luo W, Yuan P, Liu L, Zhou Y. Liver macrophages mediate effects of downhill running and caloric restriction on nonalcoholic fatty liver disease of high fat diet-fed mice. Life Sci 2020;256:117978. [PMID: 32553927 DOI: 10.1016/j.lfs.2020.117978] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Lonardo A, Ballestri S. Perspectives of nonalcoholic fatty liver disease research: a personal point of view. Exploration of Medicine 2020;1:85-107. [DOI: 10.37349/emed.2020.00007] [Cited by in Crossref: 9] [Article Influence: 4.5] [Reference Citation Analysis]
12 Lonardo A, Ballestri S. Perspectives of nonalcoholic fatty liver disease research: a personal point of view. Exploration of Medicine 2020;1:85-107. [DOI: 10.37349/emed.2020.00007] [Reference Citation Analysis]
13 Marin-Alejandre BA, Abete I, Cantero I, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Quiroga J, Martinez-Echeverria A, Uriz-Otano JI, Huarte-Muniesa MP, Tur JA, Martinez JA, Zulet MA. The Metabolic and Hepatic Impact of Two Personalized Dietary Strategies in Subjects with Obesity and Nonalcoholic Fatty Liver Disease: The Fatty Liver in Obesity (FLiO) Randomized Controlled Trial. Nutrients 2019;11:E2543. [PMID: 31652512 DOI: 10.3390/nu11102543] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
14 Ismaiel A, Dumitraşcu DL. Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review. Front Med (Lausanne) 2019;6:202. [PMID: 31616668 DOI: 10.3389/fmed.2019.00202] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 12.3] [Reference Citation Analysis]
15 Khoo J, Hsiang JC, Taneja R, Koo SH, Soon GH, Kam CJ, Law NM, Ang TL. Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease. Liver Int. 2019;39:941-949. [PMID: 30721572 DOI: 10.1111/liv.14065] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
16 Santos RD, Valenti L, Romeo S. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. Atherosclerosis 2019;282:110-20. [PMID: 30731283 DOI: 10.1016/j.atherosclerosis.2019.01.029] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 12.0] [Reference Citation Analysis]
17 Ilan Y. Future of Treatment for Nonalcoholic Steatohepatitis: Can the Use of Safe, Evidence-Based, Clinically Proven Supplements Provide the Answer to the Unmet Need? Dig Dis Sci 2018;63:1726-36. [DOI: 10.1007/s10620-018-5080-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
18 Iogna Prat L, Tsochatzis EA. The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). Hormones 2018;17:219-29. [DOI: 10.1007/s42000-018-0021-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
19 Ampuero J, Sánchez-torrijos Y, Aguilera V, Bellido F, Romero-gómez M. Nuevas perspectivas terapéuticas en la esteatohepatitis no alcohólica. Gastroenterología y Hepatología 2018;41:128-42. [DOI: 10.1016/j.gastrohep.2017.07.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Puoti C, Elmo MG, Ceccarelli D, Ditrinco M. Liver steatosis: The new epidemic of the Third Millennium. Benign liver state or silent killer? European Journal of Internal Medicine 2017;46:1-5. [DOI: 10.1016/j.ejim.2017.06.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
21 Barrea L, Di Somma C, Muscogiuri G, Tarantino G, Tenore GC, Orio F, Colao A, Savastano S. Nutrition, inflammation and liver-spleen axis. Critical Reviews in Food Science and Nutrition 2018;58:3141-58. [DOI: 10.1080/10408398.2017.1353479] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
22 Eslamparast T, Tandon P, Raman M. Dietary Composition Independent of Weight Loss in the Management of Non-Alcoholic Fatty Liver Disease. Nutrients. 2017;9. [PMID: 28933748 DOI: 10.3390/nu9080800] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 8.6] [Reference Citation Analysis]
23 Tilg H. How to Approach a Patient With Nonalcoholic Fatty Liver Disease. Gastroenterology 2017;153:345-9. [PMID: 28647352 DOI: 10.1053/j.gastro.2017.06.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
24 Zhao L, Cang Z, Sun H, Nie X, Wang N, Lu Y. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease. BMC Endocr Disord 2017;17:13. [PMID: 28241817 DOI: 10.1186/s12902-017-0165-7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 8.4] [Reference Citation Analysis]
25 Marcellin P, Estrabaud E. Recent advances in hepatology. Liver Int 2017;37:3-6. [DOI: 10.1111/liv.13323] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]